24/7 Market News Snapshot 17 June, 2025 – CERo Therapeutics Holdings, Inc. Common Stock (NASDAQ:CERO)

June 17, 2025

DENVER, Colo., 17 June, 2025 (www.247marketnews.com) – (Nasdaq:CERO) are discussed in this article.
CERo Therapeutics Holdings, Inc. (Nasdaq:CERO) has captured the market’s attention with recent developments driving its stock to an impressive pre-market increase of 75.98%, climbing to $12.09 from $6.87. Trading volumes reached a notable 7.44 million shares, indicating vigorous investor enthusiasm and a bullish outlook for the company’s future.

This spike in demand coincides with the announcement that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CERo’s lead drug candidate, CER-1236, for the treatment of acute myeloid leukemia (AML). The ODD highlights the significant unmet medical needs within the oncology segment, particularly for innovative therapies aimed at rare diseases.

CER-1236 is poised to revolutionize AML treatment through its unique mechanism of action, which enhances the patient’s own T cells by enabling them to effectively target and eliminate cancerous cells. Currently undergoing Phase 1 clinical trials, the drug is being evaluated in a multi-center, open-label study designed to determine its safety and preliminary efficacy in patients with relapsed or refractory AML, along with those newly diagnosed with specific genetic mutations.

The trial consists of two parts: an initial dose-escalation phase to establish the maximum tolerated dose, followed by an expansion phase to further assess safety and efficacy. Key outcomes include monitoring adverse events and evaluating overall response rates, along with comprehensive pharmacokinetic analyses.

According to CEO Chris Ehrlich, the Orphan Drug Designation affirms the company’s commitment to pioneering transformative cancer treatments. He expressed optimism about the company’s journey and the potential impact of CER-1236. The ODD also affords CERo vital incentives, such as guidance in clinical trial design and added market exclusivity post-approval, reinforcing its mission to advance innovative immunotherapy solutions.

Related news for (CERO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.